Related Experiment Video
Updated: Jul 26, 2026

Calculating Heart Rate Variability from ECG Data from Youth with Cerebral Palsy During Active Video Game Sessions
Published on: June 5, 2019
Heart rate variability and progression of coronary atherosclerosis
H V Huikuri1, V Jokinen, M Syvänne
1Division of Cardiology, Department of Medicine and Biocenter of Oulu, University of Oulu, Finland. HEIKKI.HUIKURI@oulu.fi
Insights
Low heart rate variability, measured by standard deviation of normal to normal R-R intervals (SDNN), is linked to faster coronary atherosclerosis progression. Gemfibrozil therapy abolished this association, indicating HR variability as a key predictor of cardiovascular disease progression.
Area of Science:
- Cardiology
- Medical Research
Background:
- Low heart rate (HR) variability is a known risk factor for cardiovascular morbidity and mortality.
- The underlying mechanisms linking reduced HR variability to cardiovascular disease progression remain unclear.
Purpose of the Study:
- To investigate the hypothesis that reduced HR variability is associated with the progression of coronary atherosclerosis.
- To evaluate the impact of gemfibrozil therapy on this association.
Main Methods:
- Prospective study analyzing 12-hour ambulatory ECG recordings from 265 patients with coronary artery disease.
- Coronary atherosclerosis progression assessed via quantitative analysis of angiograms over an average of 32 months.
- Patients were randomized to placebo or gemfibrozil therapy.
Main Results:
- Lower standard deviation of normal to normal R-R intervals (SDNN) correlated with more significant coronary atherosclerosis progression in the placebo group.
- Gemfibrozil therapy eliminated the association between SDNN and atherosclerosis progression.
- SDNN independently predicted focal coronary atherosclerosis progression in multiple regression analysis.
Conclusions:
- Reduced HR variability, specifically lower SDNN, is an independent predictor of accelerated coronary atherosclerosis progression.
- HR variability provides prognostic information beyond traditional cardiovascular risk markers.
- Gemfibrozil may mitigate the progression of coronary atherosclerosis associated with low HR variability.
Abstract:
Low heart rate (HR) variability is associated with increased risk of cardiovascular morbidity and mortality, but the causes and mechanisms of this association are not well known. This prospective study was designed to test the hypothesis that reduced HR variability is related to progression of coronary atherosclerosis. Average HR and HR variability were analyzed in 12-hour ambulatory ECG recordings from 265 qualified patients participating in a multicenter study to evaluate the angiographic progression of coronary artery disease in patients with prior coronary artery bypass surgery and low high-density lipoprotein cholesterol concentrations (<1.1 mmol/L). Participants were randomized to receive a placebo or gemfibrozil therapy. The progression of coronary atherosclerosis was estimated by quantitative, computer-assisted analysis of coronary artery stenoses from the baseline angiograms and from repeated angiograms performed an average of 32 months later. The progression of focal coronary atherosclerosis of the patients randomized to placebo therapy was more marked in the tertile with the lowest standard deviation of all normal to normal R-R intervals (SDNN, 74+/-13 ms; mean decrease in the per-patient minimum luminal diameter -0.17 mm; 95% confidence interval [CI], -0.23 to -0.12 mm) than in the middle tertile (SDNN, 107+/-7 ms; mean decrease -0.05 mm; 95% CI, -0.08 to -0.01 mm) or highest tertile (SDNN, 145+/-25 ms; mean change 0.01 mm; 95% CI, -0. 04 to 0.02 mm) (P<0.001 between the tertiles). This association was abolished by gemfibrozil. SDNN was lower (P<0.001) and minimum HR was faster (P<0.01) in the patients with marked progression than in those with regression of focal coronary atherosclerosis. In multiple regression analysis including HR variability, minimum HR, demographic and clinical variables, smoking, blood pressure, glucose, lipid measurements and lipid-modifying therapy, progression of focal coronary atherosclerosis was independently predicted by the SDNN (beta=0.24; P=0.0001). Low HR variability analyzed from ambulatory ECG predicts rapid progression of coronary artery disease. HR variability provided information on progression of focal coronary atherosclerosis beyond that obtained by traditional risk markers of atherosclerosis.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Related Concept Videos
Factors Influencing Heart Rate
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
Regulation of Heart Rates
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Cardiac Output I:Effect of Heart Rate on Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart rate...
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests